Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Ogo dị elu
Mbubata Azụmahịa Molnupiravir na ndị emetụtara nwere ogo dị elu
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Aha Chemical | Molnupiravir (EIDD-2801) |
| Ụdị okwu | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropyl ester;((2R,3S,4R,5R) -3,4-dihydroxy-5-((E) -4- (hydroxyimino) -2-oxo-3,4-dihydropyrimidin-1 (2H) -yl) tetrahydrofuran-2 -yl) methyl isobutyrate |
| Nọmba CAS | 2349386-89-4 |
| Nọmba CAT | RF-API97 |
| Ọnọdụ Ahịa | Na Akụrụngwa, Mpụta Ihe ruru narị narị kilograms |
| Usoro ihe omimi | C13H19N3O7 |
| Ibu molekụla | 329.31 |
| Solubility | Soluble na DMSO |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
| njirimara IR | Sample Spectrum kwekọrọ na ọkọlọtọ ntụaka |
| njirimara HPLC | Oge njide nke nnukwu ọnụ ọgụgụ kachasị elu nke ngwọta nlele dabara na nke ọkọlọtọ ọkọlọtọ |
| Ihe ndị emetụtara | |
| adịghị ọcha A | ≤0.15% |
| adịghị ọcha B | ≤0.15% |
| Ọdịghị ọcha ọ bụla akọwapụtaghị | ≤0.15% |
| Mgbakọta adịghị ọcha akọwapụtaghị | ≤0.30% |
| Mgbakọta adịghị ọcha | ≤0.50% |
| Ihe mgbaze fọdụrụnụ | |
| N-Heptane | ≤5000ppm |
| Ethanol | ≤5000ppm |
| Isopropyl acetate | ≤5000ppm |
| Acetonitrile | ≤410ppm |
| Methylene dichloride | ≤600ppm |
| Acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Ọdịnaya Mmiri (KF) | ≤0.50% |
| Ihe fọdụrụ na mgbanye | ≤0.10% |
| Ntụgharị anya | -7.5° ruo -9.5° (C=0.5, methanol) |
| Ọla dị arọ | ≤10ppm |
| Ụzọ ịdị ọcha / nyocha | ≥99.5% (230nm) |
| Usoro nyocha / nyocha | 98.0% ~ 102.0% (HPLC na ntọala a mịrị amị) |
| Ndụ shelf | Ọnwa 24 |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
| Ojiji | API, Molnupiravir (EIDD-2801) Ihe mgbochi COVID-19 |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
Molnupiravir (EIDD-2801, MK-4482) bụ ọgwụ a na-ahụ maka ọnụ nke ribonucleoside analogue β-d-N4-hydroxycytidine (NHC; EIDD-1931) nwere nnukwu ọrụ mgbochi nje megide SARS-CoV-2, MERS-CoV, SARS-CoV, na onye na-akpata COVID-19.A na-ere Molnupiravir n'okpuru akara aha Lagevrio yana n'ozuzu ya dị ka emorivir.E gosiputara Molnupiravir iji meziwanye ọrụ akpa ume, ibelata ibu ahụ ma belata ọnụọgụ nje na ngụgụ.Na mgbakwunye na ọrụ megide coronaviruses, Molnupiravir, na nyocha ụlọ nyocha, egosipụtala ọrụ megide nje influenza oge na nnụnụ, nje syncytial iku ume, nje chikungunya, nje Ebola, nje virus equine nke Venezuelan, na nje encephalitis equine Eastern.Emebere Molnupiravir ka ọ na-agwọ ọrịa influenza na Mahadum Emory site n'aka ụlọ ọrụ na-emepụta ọgwụ ọhụrụ nke mahadum, Drug Innovation Ventures at Emory (DRIVE), mana a na-akọ na agbahapụla ya maka nchegbu mutagenicity.Ụlọ ọrụ Ridgeback Biotherapeutics nke Miami nwetara ya, bụ nke mechara soro Merck & Co. kwalite ọgwụ ahụ n'ihu.A kwadoro Molnupiravir maka ojiji ahụike na United Kingdom na Nọvemba 2021.
